Cardamyst FDA approval and launch for PSVT, solid cash, and big expansion upside. Click for more on MIST stock.

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...

The US Food and Drug Administration has approved etripamil nasal spray (Cardamyst) for adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT), drugmaker Milestone ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that the U.S. Food and Drug Administration has approved its first commercial product, CARDAMYST (etripamil) nasal spray. The prescription ...

Paroxysmal supraventricular tachycardia (PSVT) is a common rapid arrhythmia observed in clinical settings, characterized by abrupt and sustained episodes lasting minutes to hours. It presents ...

A randomized clinical trial found that among people with a history of Atrial fibrillation (AFib) or related rhythm issues, drinking at least one cup of caffeinated coffee daily was associated with a ...

Nov. 18, 2025 – If you're among the 1 in 5 U.S. adults who have an abnormal heart rhythm problem called atrial fibrillation, there's been a flurry of new research about the condition that offers some ...

Sweden’s public broadcaster edited President Donald Trump's January 6 speech in a way that misrepresented his message, much as the BBC has been accused of doing, the Kvartal newspaper has reported.

Moderate coffee consumption may reduce AF recurrence risk post-cardioversion, contradicting traditional advice to avoid caffeine. The DECAF trial showed a 39% lower recurrence risk in coffee drinkers ...